Targeted treatment before and after surgery for lung cancer with BRAF or MET changes
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a targeted treatment given before and after surgery for people with a specific type of early-stage lung cancer that has a BRAF V600 or MET exon 14 mutation. The goal is to see if the treatment helps shrink the tumor before surgery and prevent it from coming back afterward.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your lung cancer is stage IB to IIIA, or a specific type of stage IIIB (called T3N2 or T4N2), and your doctor plans to remove it with surgery.
- Your tumor has a specific genetic change called BRAF V600 or MET exon 14 mutation (confirmed by a special lab test).
- You have not had any previous cancer treatment for this lung cancer.
- You are in good overall health (able to do daily activities without help, ECOG score 0 or 1).
- You do not have cancer that has spread to the brain, other forms of lung cancer (like neuroendocrine), or certain other health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests an immunotherapy treatment given before surgery for people with stage IIB to IIIB non-small cell lung cancer (NSCLC) that has specific rare “driver” gene changes. The goal is to shrink the cancer and improve outcomes by treating it earlier with the immune system.
This trial tests a drug called vebreltinib before surgery for people with a specific type of lung cancer (MET exon 14 skipping mutation) that is at a stage where it can be removed. The goal is to see if the drug can shrink the tumor before surgery, making the operation more successful.
This trial tests whether adding aspirin to the targeted drugs dabrafenib and trametinib can work better for advanced lung cancer that has a specific gene change (BRAF V600E). The goal is to see if the combination helps slow the cancer or shrink tumors.
This trial tests dabrafenib plus trametinib in people whose solid tumors have a BRAF V600E mutation that cannot be fully removed by surgery or has spread. It looks at whether these targeted medicines can shrink tumors and control the disease.
This trial tests whether taking two targeted drugs (dabrafenib and trametinib) before surgery can shrink a specific type of jaw tumor called ameloblastoma. The tumor must have a certain genetic change (BRAF V600E mutation) and require a large jaw surgery. The goal is to see if the drugs make surgery less extensive or more successful.
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
Hear when a new BRAF V600 Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.